Chiara Nicolò1,2, Cynthia Périer1,2, Melanie Prague3,4, Carine Bellera4,5, Gaëtan MacGrogan6,7, Olivier Saut1,2, Sébastien Benzekry1,2. 1. Mathematical Modeling for Oncology Team, Inria Bordeaux Sud-Ouest, Talence, France. 2. Institut de Mathématiques de Bordeaux, UMR 5251, CNRS, Bordeaux, France. 3. Statistics in Systems Biology and Translational Medicine Team, Inria Bordeaux Sud-Ouest, University of Bordeaux, Bordeaux, France. 4. INSERM U1219, Bordeaux Public Health, University of Bordeaux, Bordeaux, France. 5. Department of Clinical Epidemiology and Clinical Research, Institut Bergonié, Regional Comprehensive Cancer Centre, Bordeaux, France. 6. Department of Biopathology, Institut Bergonié, Regional Comprehensive Cancer Centre, Bordeaux, France. 7. INSERM U1218, Bordeaux Public Health, University of Bordeaux, Bordeaux, France.
Abstract
PURPOSE: For patients with early-stage breast cancer, predicting the risk of metastatic relapse is of crucial importance. Existing predictive models rely on agnostic survival analysis statistical tools (eg, Cox regression). Here we define and evaluate the predictive ability of a mechanistic model for time to distant metastatic relapse. METHODS: The data we used for our model consisted of 642 patients with 21 clinicopathologic variables. A mechanistic model was developed on the basis of two intrinsic mechanisms of metastatic progression: growth (parameter α) and dissemination (parameter μ). Population statistical distributions of the parameters were inferred using mixed-effects modeling. A random survival forest analysis was used to select a minimal set of five covariates with the best predictive power. These were further considered to individually predict the model parameters by using a backward selection approach. Predictive performances were compared with classic Cox regression and machine learning algorithms. RESULTS: The mechanistic model was able to accurately fit the data. Covariate analysis revealed statistically significant association of Ki67 expression with α (P = .001) and EGFR expression with μ (P = .009). The model achieved a c-index of 0.65 (95% CI, 0.60 to 0.71) in cross-validation and had predictive performance similar to that of random survival forest (95% CI, 0.66 to 0.69) and Cox regression (95% CI, 0.62 to 0.67) as well as machine learning classification algorithms. CONCLUSION: By providing informative estimates of the invisible metastatic burden at the time of diagnosis and forward simulations of metastatic growth, the proposed model could be used as a personalized prediction tool for routine management of patients with breast cancer.
PURPOSE: For patients with early-stage breast cancer, predicting the risk of metastatic relapse is of crucial importance. Existing predictive models rely on agnostic survival analysis statistical tools (eg, Cox regression). Here we define and evaluate the predictive ability of a mechanistic model for time to distant metastatic relapse. METHODS: The data we used for our model consisted of 642 patients with 21 clinicopathologic variables. A mechanistic model was developed on the basis of two intrinsic mechanisms of metastatic progression: growth (parameter α) and dissemination (parameter μ). Population statistical distributions of the parameters were inferred using mixed-effects modeling. A random survival forest analysis was used to select a minimal set of five covariates with the best predictive power. These were further considered to individually predict the model parameters by using a backward selection approach. Predictive performances were compared with classic Cox regression and machine learning algorithms. RESULTS: The mechanistic model was able to accurately fit the data. Covariate analysis revealed statistically significant association of Ki67 expression with α (P = .001) and EGFR expression with μ (P = .009). The model achieved a c-index of 0.65 (95% CI, 0.60 to 0.71) in cross-validation and had predictive performance similar to that of random survival forest (95% CI, 0.66 to 0.69) and Cox regression (95% CI, 0.62 to 0.67) as well as machine learning classification algorithms. CONCLUSION: By providing informative estimates of the invisible metastatic burden at the time of diagnosis and forward simulations of metastatic growth, the proposed model could be used as a personalized prediction tool for routine management of patients with breast cancer.
Authors: Chengyue Wu; Guillermo Lorenzo; David A Hormuth; Ernesto A B F Lima; Kalina P Slavkova; Julie C DiCarlo; John Virostko; Caleb M Phillips; Debra Patt; Caroline Chung; Thomas E Yankeelov Journal: Biophys Rev (Melville) Date: 2022-05-17
Authors: Clement G Yedjou; Solange S Tchounwou; Richard A Aló; Rashid Elhag; BereKet Mochona; Lekan Latinwo Journal: Int J Sci Acad Res Date: 2021-10-30
Authors: Laura B Zwep; Kevin L W Duisters; Martijn Jansen; Tingjie Guo; Jacqueline J Meulman; Parth J Upadhyay; J G Coen van Hasselt Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-04-08